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Abstract
Background: Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M; PCK2) is expressed in all cancer types
examined and in neuroprogenitor cells. The gene is upregulated by amino acid limitation and ER-stress in an ATF4-
dependent manner, and its activity modulates the PEP/Ca2+ signaling axis, providing clear arguments for a
functional relationship with metabolic adaptations for cell survival. Despite its potential relevance to cancer
metabolism, the mechanisms responsible for its pro-survival activity have not been completely elucidated.
Methods: [U-13C]glutamine and [U-13C]glucose labeling of glycolytic and TCA cycle intermediates and their
anabolic end-products was evaluated quantitatively using LC/MS and GC/MS in conditions of abundant glucose
and glucose limitation in loss-of-function (shRNA) and gain-of-function (lentiviral constitutive overexpression) HeLa
cervix carcinoma cell models. Cell viability was assessed in conjunction with various glucose concentrations and in
xenografts in vivo.
Results: PEPCK-M levels linearly correlated with [U-13C]glutamine label abundance in most glycolytic and TCA cycle
intermediate pools under nutritional stress. In particular, serine, glycine, and proline metabolism, and the anabolic
potential of the cell, were sensitive to PEPCK-M activity. Therefore, cell viability defects could be rescued by
supplementing with an excess of those amino acids. PEPCK-M silenced or inhibited cells in the presence of
abundant glucose showed limited growth secondary to TCA cycle blockade and increased ROS.
In limiting glucose conditions, downregulation of PKC-ζ tumor suppressor has been shown to enhance survival.
Consistently, HeLa cells also sustained a survival advantage when PKC-ζ tumor suppressor was downregulated using
shRNA, but this advantage was abolished in the absence of PEPCK-M, as its inhibition restores cell growth to
control levels. The relationship between these two pathways is also highlighted by the anti-correlation observed
between PEPCK-M and PKC-ζ protein levels in all clones tested, suggesting co-regulation in the absence of glucose.
Finally, PEPCK-M loss negatively impacted on anchorage-independent colony formation and xenograft growth
in vivo.
Conclusions: All in all, our data suggest that PEPCK-M might participate in the mechanisms to regulate proteostasis
in the anabolic and stalling phases of tumor growth. We provide molecular clues into the clinical relevance of
PEPCK-M as a mechanism of evasion of cancer cells in conditions of nutrient stress.
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Background
Phosphoenolpyruvate carboxykinase (PEPCK) (GTP; EC
4.1.1.32) catalyzes the GTP-dependent conversion of oxa-
loacetate (OAA) to phosphoenolpyruvate (PEP) from two
enzymatically indistinct isozymes localized to the cytosol
(PEPCK-C) or the mitochondria (PEPCK-M) [1, 2] and
encoded by different nuclear genes (PCK1 and PCK2, re-
spectively) [3]. Interestingly, both isozymes are differen-
tially expressed and regulated. Whereas PEPCK-C is
restricted to gluconeogenic and glyceroneogenic tissues
(liver, small intestine, kidney cortex, and adipose tissue)
and responds to insulin, glucagon, and dexamethasone,
PEPCK-M is only stimulated by ER-stress effectors and it
is widely expressed (i.e., T and B cells, pancreatic β cells,
liver, neurons, and undifferentiated tissues such as embry-
onic stem cells and tumors). PEPCK-M effects on hepatic
gluconeogenesis have been recently demonstrated [4], but
its role remains elusive in non-gluconeogenic tissues such
as tumor cells.
We identified PCK2 as a target gene for ATF4, the
master regulator of ER and amino acid stress path-
ways. PEPCK-M was upregulated by effectors of this
pathway by recruiting ATF4 to a consensus AARE
site located at the PEPCK-M proximal promoter [5].
In these conditions, PEPCK-M activity is necessary to
tip the balance towards cell survival. The importance
of chronic ER stress in proper adaptive responses in
cancer cells in vivo as part of their metabolic repro-
gramming hallmark for tumor progression bears
weight to the significance of this pathway in tumor
survival and progression.
Consistent with this view, we and others have demon-
strated the relevance of PEPCK-M in cell growth and
chemoresistance in several cancer cell models in vitro
and in vivo [6–9]. However, the way PEPCK-M fluxes
interact with tumor cell metabolism to promote survival
are yet to be identified, and is the focus of the present
work. On this, we have recently shown that PEPCK-M
activity, and glucose availability, modulates cytosolic cal-
cium signaling by upkeeping the pool of PEP, an inhibi-
tor of SERCA, even in the presence of glucose in two
models of colon carcinoma, HCT116 and SW480 [6].
Calcium then signals downstream effectors such as
NFAT and c-Myc with implications on tumor cell biol-
ogy. Thus, this regulatory axis is not only dependent on
glucose availability but also on general nutritional status
as PEPCK-M can flux carbons from several sources into
the glycolytic pool.
We describe here the role of PEPCK-M in the preser-
vation of the capacity for growth and survival in the can-
cer cell by ensuring the biosynthesis of amino acids such
as proline, serine, and glycine. This pathway is important
to offset glucose carbons with carbons from other
sources such as glutamine or lactate, maintaining the
TCA cycle, and in doing so, affect the general anabolic
potential of the cell and its health status. Consistently,
potentiation of resistance to glucose deprivation by the
loss of PKC-ζ, a tumor suppressor [10], required
PEPCK-M activity demonstrating that this enzyme
serves an adaptative role in cancer metabolism, with sig-
nificance in tumor growth, and further validates its po-
tential as a therapeutic target.
Methods
Cell culture
Cervix (HeLa), and colon (HCT116 and SW480) carcinoma
cell lines, and mouse Kras-V12 carcinogenic NIH-3T3
(NIH-3T3Kras) (a gift from Dr. Capella, IDIBELL, Spain)
were cultured in DMEM supplemented with 10% FBS, 100
units/ml penicillin, 10 g/ml streptomycin, and 2mML-glu-
tamine (all from Biological Industries, Israel) and incubated
in a humidified atmosphere of 5% CO2 at 37 °C.
For experiments, unless stated otherwise, cells were
grown in DMEM media with different glucose concen-
trations: 25 mM glucose (high glucose), 1 mM glucose
(glucose exhaustion), and 0 mM glucose (glucose
deprivation). Media were supplemented with 10% FBS,
100 units/ml penicillin, 10 g/ml streptomycin, and 2mM
or 4mM (glucose deprivation) L-glutamine.
RNA extraction and quantitative RT-PCR
Total RNA was extracted with the TRIsureTM RNA iso-
lation system (Bioline, Memphis, TN, USA) and tran-
scribed with High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA). QRT-
PCR was performed using the TaqMan gene expression
assay and 7900HT Real-Time RT-PCR system (Applied
Biosystems, Carlsbad, CA, USA). Data were analyzed by
the ΔΔCt method to normalize with TBP and GUSB
expression.
Western blot
Cells were homogenized in RIPA buffer supplemented
with protease and phosphatase inhibitors and centri-
fuged at 15,000 g for 15 min at 4 °C. Protein concentra-
tion was determined using the BCA protein assay kit
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(Thermo Scientific, Rockford, IL, USA), and equal
amounts of protein (20–30 μg) were subjected to 8–12%
SDS-PAGE and transferred to an Immobilon membrane
(Millipore, Bedford, CA, USA). Blots were treated with
primary antibodies, followed by the corresponding second-
ary antibody with horseradish peroxidase activity. Blots
were developed using Pierce ECL reagent (Thermo Fisher
Scientific, Waltham, MA, USA) in a Fujifilm LAS 3000 In-
telligent Dark Box IV imaging system (Tokyo, Japan).
The following primary antibodies were used: anti-
PEPCK-M (ab70359, Abcam, Cambridge, UK), anti-
PEPCK-C (generous gift of Dr. Daryl K. Granner, Van-
derbilt University, Nashville, TN, USA), anti-SOD2
(ab13534, Abcam), anti-p53 (ab26, Abcam), anti-p21
(sc397, Santa Cruz Biotechnology, Dallas, TX, USA),
anti-gamma tubulin (T6557, Sigma-Aldrich, St. Louis,
MO, USA), and anti-PKC-ζ (9372S, Cell Signaling Tech-
nology, Danver, MA, USA).
Transduction
Protocols were performed as recommended by the
manufacturer. For PCK2 knockdown, HeLa cells were
infected with GIPZ Lentiviral TurboGFP shRNAs (Dhar-
maco, Lafayette, CO, USA; clone IDs: V3LMM_427490
and V3LHS_328126) and denominated sh1-PCK2 and
sh2-PCK2, respectively. GIPZ non-targeting lentiviral
TurboGFP shRNA (Dharmacon; clone ID RHS-4348)
was used to produce negative control cells denominated
shCtrl. After transduction, cells were selected with 1 μg/ml
puromycin for 1week. For overexpression of PCK2, HeLa
cells were infected with a PCK2 Human ORFeome lentiviral
particles (GeneCopoeia, Rockville, MD, USA; clone ID: LP-
OL06695-LX304-0200-S) and denominated L-PCK2. Cells
were selected with 2 μg/ml blasticidin for 1week.
For PKC-ζ knockdown, HeLa and SW480 cells were
infected with GIPZ Lentiviral TurboGFP shRNAs (Dhar-
macon; clone IDs: V3LHS_635000, V3LHS_372773,
V3LHS_641464) and denominated shPKCζ #37, shPKCζ
#63, and shPKCζ #64, respectively. The negative control,
shPKCζ #Ctrl, was produced by infecting HeLa cells with
GIPZ non-targeting lentiviral TurboGFP shRNA (Dhar-
macon; clone ID: RHS-4348). After transduction, cells
were selected with 1 μg/ml puromycin for 1 week.
Establishment of PCK2 knockout SW480 cell line with
CRISPR/Cas 9 system
To generate a pool of SW480 cells lacking PCK2 (PCK2
CRISPR/Cas9 KO), guide RNAs (gRNA) designed to tar-
get PCK2 were synthesized, and annealed and cloned
into the pSpCas9(BB)-2A-puro vector (Adgene, Water-
town, MA, USA) as described previously [11], using an
online gRNA design tool (CHOPCHOP; https://chop-
chop.cbu.uib.no). After 24 h post-transfection, puro-
mycin was added for 24 h at 2 μg/ml for selection and
subsequently single cells were selected in 96-well plates.
The selected cells were tested for gene deletion by endo-
nuclease assay and checked for protein knockdown by
Western blot.
PEPCK-M enzymatic activity
Cell extracts from confluent 150 cm2 tissue culture
dishes were washed twice in PBS, trypsinized, and cen-
trifuged at 150 g for 3 min at 4 °C. Cells were resus-
pended in 200 μl of ice-cold homogenization buffer (100
mM HEPES-NaOH pH 7.2, 0.1% triton™ X-100, 2.5 mM
DTT) and lysed by performing 2 freeze/thaw cycles. Ho-
mogenates were cleared by centrifugation at 100000 g
for 1 h at 4 °C. PEPCK-M activity was measured in the
direction of phosphoenolpyruvate formation. Briefly, the
reaction consisted of 100 mM of HEPES-NaOH (pH 7.2),
3 mM malic acid, 3 mM NAD, 2 mM MgCl2, 0.2 mM
MnCl2, 37 mM DTT, 6 U/ml MDH, and the reaction
was started by the addition of 0.2 mM of GTP. The
amount of produced NADH is proportional to PEPCK
activity. Reads were measured at 340 nm at 37 °C in a
total volume of 1 ml using a DU® 800 spectrophotometer
(Beckman Coulter, Brea, CA, USA).
Immunohistochemistry
Tissue microarray panel (BCN962, Biomax, Rockville,
MD, USA) containing multiple organ carcinoma and ad-
jacent normal tissue was deparaffinized and rehydrated
according to standard procedures. Antigen retrieval was
performed by heating the slide in 10mM sodium citrate
buffer (pH 6) in a pressure cooker. The highest pressure
was maintained for 3 min, and samples were let to cool
down for 20min. Endogenous peroxidase activity was
inactivated by incubating samples in 6% H2O2 for 15min.
Samples were blocked with 20% goat serum in PBS
and then incubated ON with primary antibody against
PEPCK-M (ab70359, Abcam) and peroxidase-based sec-
ondary anti-goat antibody. Antigen-antibody complexes
were detected with a DAB peroxidase substrate kit
(Dako Agilent, Santa Clara, CA, USA) according to the
manufacturer’s protocol. Samples were counterstained
with hematoxylin, dehydrated, and mounted with DPX.
Fluorescent preparations were visualized, and images
were captured with Nikon Eclipse 800 light microscope
(Nikon, Tokyo, Japan).
MTT assay
To assess cell viability, 0.5 mg/ml of MTT (M2128,
Sigma-Aldrich, St. Louis, MO, USA) diluted in DMEM
without phenol red was added to each well, and plates
were incubated at 37 °C, 5% CO2 for 2 h. The formazan
product was dissolved in isopropanol, and the absorb-
ance of samples was measured using a microplate reader
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at a wavelength of 570 nm with background subtraction
at 650 nm.
Soft agar colony formation assay
Anchorage-independent growth was determined by plat-
ing 5000 cells in 1 ml of 0.35% agarose in 6 well plates.
0.7% agarose was mixed in a 1:1 ratio with DMEM
media, supplemented with 10% FCS, 2 mM glutamine,
and 1mM or 25mM glucose, respectively. A layer con-
taining cells was overlaid on 0.5% agar in mQ water.
Cells were fed with corresponding DMEM media and
refed every 3–4 days. After 2 weeks, colonies were
stained with MTT and counted.
MitoSOX staining
MitoSOX™ Red mitochondrial superoxide indicator
(M36008, ThermoFisher Scientific, Waltham, MA, USA)
was used to measure the production of superoxide in
mitochondria. Cells were treated with 5 μM MitoSOX™
Red in HBSS/Ca/Mg for 15 min at 37 °C and 5% CO2
protected from light. Cells were washed with HBSS/Ca/
Mg. Subsequently, cells were trypsinized, resuspended in
corresponding DMEM media without phenol red, and
analyzed by flow cytometry with Gallios™ flow cytometer
(Beckman Coulter).
Metabolomics
Cells were plated in 6-well plates at 0.25 × 106 cells/well
and grown overnight in a growth medium. Next day,
cells were washed with PBS and pre-treated with
medium lacking glucose for 3 h and glucose-deprived
medium supplemented with dialyzed FCS (dFCS) and 2
mM uniformly labeled [U-13C]glutamine was added for
4 h. In the case of high-glucose media (25 mM glucose),
cells were pretreated with fresh complete DMEM media
for 3 h and subsequently treated with DMEM media
supplemented with dFCS and 2mM [U-13C]glutamine
for 4 h. At the end of cultivation, cells were washed
twice with cold PBS, snap-frozen with liquid nitrogen,
and harvested using an aqueous solution of MeOH
(MeOH (80%)/H2O (20%)). The concentration of metab-
olites was analyzed by using mass spectrometer API
3200 triple quadrupole LC-MS/MS. Enrichment studies
were analyzed by using GC/MS spectrometry (GC/MS
Agilent 5975C). Proline enrichment and concentration
of TCA cycle intermediates were analyzed in cells har-
vested in 1.8 ml of cold methanol/chloroform (2:1, v:v)
and analyzed by using GC/MS spectrometry.
Glucose assay
Glucose concentration in media was determined by col-
orimetry assay using a glucose oxidase and peroxidase
method as recommended by manufacturer PGO (P7119,
Sigma-Aldrich, Darmstadt, Germany). Absorbance was
measured at 450 nm after 30 min of incubation at 37 °C.
Xenograft models
5 × 106 of SW480 WT or SW480 PCK2 CRISPR/Cas9
KO was injected in both flanks of female 5–6-week-old
BALB/c nude mice (at least n = 3 per group). Similarly,
1 × 106 of HeLa shCtrl, sh1-PCK2, or sh2-PCK2 was
injected in two mammary fat pads of female 5–6-week-
old BALB/c nude mice (at least n = 8 per group). Tumor
volume was measured by calipering in two dimensions
and calculated as [(short length × 2) × long length)]/2.
After 15 days (SW480) or 23 days (HeLa), mice were eu-
thanized by cervical dislocation, and the tumors col-
lected for further analysis. All the animal studies were
approved by the local committee for animal care (IDI-
BELL, DAAM 5766).
Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis
was performed by one-way or two-way Anova (Sidak
post hoc test) or unpaired two-tailed Student’s t test,
using GraphPad Prism® software. Significance levels are
one symbol = p < 0.05, two symbols = p < 0.01, and
three symbols = p < 0.001.
Results
The expression of PEPCK-M in healthy organisms is
mainly confined to the kidney, liver, pancreas, and small
intestine. Yet, ONCOMINE dataset mining (Supplemen-
tary Table 1) demonstrates increased PCK2 mRNA
levels upon malignant transformation in tissues where
PEPCK-M is not originally expressed (Fig. 1a). Tumors
originating from tissues where PEPCK-M is highly
expressed in humans, such as the liver, pancreas, kidney,
and gastrointestinal tract showed reduced expression. In
contrast, PCK1 (PEPCK-C) expression was low in all types
of tumors regardless of its levels in healthy tissue (Fig. 1a).
Immunohistochemical analysis of tissue microarrays
with multiple normal and cancer tissue samples con-
firmed that the PEPCK-M signal was highly associated
with malignancy, for example, in the prostate, lung,
breast, testis, and cervix carcinomas (Fig. 1b). The
healthy tissue from these organs (the glands of the pros-
tate and uterus, and cells of seminiferous tubules) was
minimally stained with PEPCK-M antibody. Finally,
PEPCK-M mRNA levels were significantly elevated in
clinical samples from cervical squamous cell carcinoma
patients as compared to normal tissue (Fig. 1c; P =
1.66E-5), from either the metastatic or the non-
metastatic dataset [12]. This points to a preferential role
of the mitochondrial isoform of PEPCK in these cancers.
A gene ontology enrichment analysis of co-expressed
genes in all available datasets of cervical cancer (Fig. 1d;
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Fig. 1 PEPCK-M is the PEPCK isoform preferentially expressed in tumors of diverse origin. a PCK1 and PCK2 expression in tumors from various
tissues (FRS stands for female reproductive system, and GIT stands for gastro-intestinal). Graphical representation of log2 median-centered ratio of
PCK1 (empty bars) and PCK2 (solid bars) present in each dataset analyzed using Oncomine at oncomine.org (analysis type: cancer versus normal,
threshold at P = 1E−5 and top gene rank 10%, see references in Supplementary Table 1). Red or black colored boxes represent overexpressed or
underexpressed for each dataset, respectively. Missing values for PCK1 expression were not significant or were not present in dataset. b
Immunohistochemical analysis of PEPCK-M expression in selected types of tumors and their matched non-neoplastic tissue microarray BCN962
(US Biomax). Tissue was briefly counterstained with hematoxylin. Scale bar = 200 μm. c PCK2 gene expression (log2) from a microarray dataset
comparing tumor samples of 35 patients with early stage cervical cancer and 5 normal cervical tissue samples. Statistical significance was
determined by unpaired two-tailed Student’s t test. d Gene ontology analysis of 100 first hits co-expressing with PCK2 in human cervical cancer
datasets analyzed using SEEK (Search-Based Exploration of Expression Compendium, Princeton), a gene co-expression search engine. q value
minimum FDR and p value adjusted per multiple hypothesis testing Benjamini-Hockberg. e, f Quantitative real-time PCR analysis of mRNA levels
of ATF4 at 6 h and 12 h (e), and selected genes at 24 h (f) in HeLa shCtrl cells grown in DMEM medium without glucose. Data is normalized to 0
h. Statistical significance compared with 0 h was determined by unpaired two-tailed Student’s t test. g, h Heatmap of amino acid distribution.
Molar fraction of AA was determined in the cell extracts of HeLa cells grown for 24 h in high-glucose (25 mM) (g) and in glucose exhaustion (1
mM) (h) conditions. Data were processed and visualized by using ClustVistool with Pareto scaling (Metsalu & Vilo, 2015). Comparison of samples is
realized within the rows
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SEEK at seek.princeton.edu) was then devised to expose
PCK2 co-expressed pathways. Interestingly, gluconeo-
genesis was not enriched, and members of this pathway
PCK1, FBP1, or G6PC1 are not co-expressors in this
analysis. The hits on the enrichment table suggest a co-
ordinated response with genes of anabolic potential, es-
pecially those related to amino acid metabolism and
biosynthetic processes. Consistently, these genes are reg-
ulated by the integrated stress response (ISR) through
ATF4 in a similar fashion to PCK2 [5], including ASNS,
GPT2, SHMT1, PHGDH, or PSAT1. Induction of ER-
stress in cervical carcinoma cells (HeLa) by glucose
deprivation showed early upregulation of ATF4 (Fig. 1e)
and other target genes of this stress response pathway
such as DDIT3, GADD34, ATF3, and EIF4EBP1 at 24 h.
As expected, PCK2 was also upregulated together with
other genes, such as ENO2, PHGDH, or PSAT1 (Fig. 1f).
All in all, this is suggesting a role for PEPCK-M within
the general TCA cycle and amino acid biosynthesis
nodes.
Thus, we examined the relative concentration
(molar fraction) of amino acids in cell extracts of
loss-of-function and gain-of-function HeLa squamous
cell cervical carcinoma cells using mass spectroscopy
(Fig. 1g, h). Amino acids with a relevant role in regu-
lating the anabolic potential of the tumor, such as
serine, glycine, proline, or threonine, showed in-
creased molar fractions with increasing PEPCK-M ex-
pression with excess glucose in the media (Fig. 1g)
and in a more physiological glucose exhaustion condi-
tion (Fig. 1h; 24 h after media refresh with 1 mM glu-
cose which is depleted within the initial 12 h; see
Supplementary Figure 2). Therefore, we focused our
attention on understanding the contribution of
PEPCK-M to the pathways involved in the synthesis
and degradation of serine, glycine, and proline.
PEPCK-M signature in tumors: serine/glycine metabolism
Direct incorporation of labeled carbons into serine and
glycine from [U-13C]glutamine was readily observed in
shCtrl cells, even in the presence of serine and glycine
(DMEM media without glucose) (Fig. 2a). Silencing
PEPCK-M as in sh1-PCK2 cells diminished the pool of
fully labeled serine by 83%. Lower enrichment was also
observed in other serine isotopologues (m + 1 was de-
creased by 82.7%, and m + 2 was 63.9% lower). Further-
more, overexpression of PEPCK-M significantly
increased the pool of labeled species of serine by 1.6-fold
(m + 3; Fig. 2a). Similarly, PEPCK-M-dependent distri-
bution of label was present in glycine, which is synthe-
sized from serine in a reaction catalyzed by serine
hydroxymethyltransferase (SHMT) (Fig. 2b). The occur-
rence of fully labeled glycine in control cells was 0.9%,
decreasing by 73.7% in PEPCK-M silenced cells (sh1-
PCK2) and increasing 1.5 times when PEPCK-M was
overexpressed (L-PCK2) (Fig. 2b).
Enrichment in serine and glycine correlated well with
PEPCK-M activity present in silenced (sh1-PCK2 and
sh2-PCK2) and overexpressed (L-PCK2) HeLa cells
(PEPCK-M protein levels were 35% (sh1-PCK2), 44%
(sh2-PCK2), and 250% (L-PCK2) of wild-type HeLa;
Supplementary Figure 1). Also, neither the parental cell
line nor any of the clones express the cytosolic isoform
of PEPCK (PEPCK-C), and therefore changes in PEPCK-
M expression do not translate to compensating upregu-
lation of PEPCK-C (Supplementary Figure 1).
Glutamine-labeled carbons were not measurable in the
serine or glycine pools when excess glucose was present
in the media (25 or 5 mM) regardless of the level of
PEPCK-M activity (Supplementary Figure 3). Longer ex-
posure of the cells to the label (24 h) was still insufficient
to achieve the incorporation of glutamine carbon into
serine or glycine in serine and glycine containing media
(DMEM) and in the absence of exogenous serine and
glycine (MEM) (Supplementary Figure 3).
The absence of serine and glycine (MEM media with-
out glucose) increased PCK2 gene expression in shCtrl
cells (Fig. 2c). In these conditions, PEPCK-M silenced
cells (sh1-PCK2) were more sensitive to serine and gly-
cine deprivation (Fig. 2d) as compared to shCtrl and
PEPCK-M overexpressing cells. Similar results were ob-
tained in HeLa wild-type cells using iPEPCK-2 [9], a po-
tent PEPCK-M inhibitor (Supplementary Figure 4).
PEPCK-M signature in tumors: proline metabolism
Next, we measured proline concentration in cell extracts
in the absence of exogenous proline (DMEM). Lower
levels of proline were observed in sh1-PCK2 cells (48.4 ±
1.02mmol/mg) when compared to shCtrl (57.78 ± 5.02
mmol/mg) and L-PCK2 (58.46 ± 1.69mmol/mg) (Fig. 3a).
More marked differences, that tightly correlated with
PEPCK-M activity, were observed under glucose exhaus-
tion; with overexpressing PEPCK-M cells showing highest
(70.25 ± 4.33mmol/mg) proline levels as compared to
shCtrl (21.13 ± 0.93mmol/mg) or sh1-PCK2 cells (5.79 ±
0.56mmol/mg).
Furthermore, L-PCK2 cells showed increased enrich-
ment of 13C carbons from [U-13C]glutamine into proline
(m + 5) as compared to reduced labels measured on the
sh1-PCK2 group (Fig. 3b), correlating with PEPCK-M
levels. In the presence of excess glucose though, fully la-
beled proline was equally enriched in all the clones (Sup-
plementary Figure 5B). In these conditions, we wanted
to examine whether the synthesis of proline from glu-
cose was being affected by the activity of PEPCK-M
measuring [U-13C]glucose (25 mM) incorporation.
PEPCK-M silencing showed a small but significant im-
pact on the incorporation of carbons from glucose into
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the proline (m + 2) pool (Fig. 3c), consistent with our
cell extract proline measurements. All in all, these data
suggest an indirect role for PEPCK-M on proline metab-
olism that depends on the metabolic status of the cell.
Reduced proline content in shCtrl and sh1-PCK2 cells
going from excess glucose to glucose exhaustion condi-
tions suggest increased proline degradation. Proline can
be metabolized to glutamate to feed the TCA cycle and
the respiratory chain. Difference in proline dehydrogen-
ase (PRODH/POX) expression between high-glucose
and glucose exhaustion condition was significantly
higher in sh1-PCK2 cells (Supplementary Figure 5A),
suggesting increased proline metabolism under this con-
dition. Interestingly, POX and PYCR1 mRNA were unre-
sponsive in cells overexpressing PCK2 (L-PCK2) when
compared high-glucose to a glucose exhaustion media
(Supplementary Figure 5A), suggestive of a certain de-
gree of resistance to the signals that activate this proline
metabolizing pathway. Furthermore, PYCR1 was signifi-
cantly increased in the presence of excess glucose exclu-
sively in L-PCK2 cells, an indication of enhanced
anabolism in these cells (Fig. 3d).
Consistent with higher utilization of proline, PRODH/
POX mRNA levels showed increased expression in sh1-
PCK2 cells both in high-glucose and glucose exhaustion
conditions (Fig. 3e) when compared to shCtrl or L-
PCK2 cells. ROS is produced during proline degradation
by PRODH/POX as an electron is passed to the electron
transport chain (ETC) (Fig. 3f) [13–15]. Indeed, sh1-
PCK2 showed increased ROS in glucose-exhaustion (Fig.
Fig. 2 PEPCK-M is essential for Ser/Gly synthesis. a, b 13C enrichment of serine and glycine in HeLa cells exposed to 2 mM [U-13C]glutamine for 4
h in the DMEM media containing 10% dFCS and 0mM glucose. Incorporation of 13C was analyzed using GC-MS. Statistical significance compared
with shCtrl was determined by unpaired two-tailed Student’s t test. c Quantitative real-time PCR analysis of PCK2 mRNA expression levels in shCtrl
HeLa cells grown in 0 mM glucose MEM media with or without 0.4 mM serine and 0.4 mM glycine (Ser/Gly) for 6 or 12 h. Values were normalized
to time 0 h. Two-way ANOVA with Sidak multiple comparison post-test analysis indicate significance of Ser/Gly effect (*). d Cell viability was
measured in HeLa cells using an MTT assay after 72 h of growth in 0 mM glucose MEM media with or without 0.4 mM serine and 0.4 mM glycine
(Ser/Gly). The sensitivity of each cell line to the addition of serine and glycine is shown as fold change with respect to the viability in the
presence of +Ser/Gly. Two-way ANOVA with Sidak multiple comparison post-test analysis indicate significance vs + Ser/Gly (*)
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3g) and glucose-abundant (Fig. 3h) conditions, as quanti-
fied using a mitochondrial ROS indicator (MitoSOX).
Interestingly, the L-PCK2 clone demonstrated reduced
ROS production in glucose exhaustion conditions be-
yond shCtrl, in parallel with higher net secretion of pro-
line into the media (Fig. 3i), further indicating a link
between proline metabolism and ROS homeostasis that
is closely associated to PEPCK-M activity in the tumor
cell. In effect, silencing PEPCK-M concurred with en-
hanced ROS-mediated signaling as evidenced by increased
SOD2 and TP53/P21 proteins in sh1-PCK2, both in the
presence of abundant glucose in the media (Fig. 3j; top
panel) and in glucose exhaustion conditions (Fig. 3j; bot-
tom panel). Also, alterations coincided with a systematic
block on the TCA cycle as the pool of most intermediates
was significantly lower in sh1-PCK2 cells (Fig. 3k).
As PEPCK-M silencing (sh1-PCK2) alters proline me-
tabolism and ROS homeostasis, we aimed to assess
whether these stimuli reduced cell viability. Indeed, via-
bility was reduced in PCK2-silenced cells and restored at
least in part by proline supplementation in the media
(Fig. 3l). This was also observed in a different model,
HCT116 colon carcinoma, after inhibition of PEPCK-M
using iPEPCK-2 (Supplementary Figure 5C).
PKC-ζ downregulation growth advantage requires PEPCK-
M activity
Several tumor survival pathways are involved in the re-
cruitment of alternative metabolic pathways, including the
downregulation of the PKC-ζ tumor suppressor [10], that
triggers the utilization of glutamine carbon when glucose
is limiting to cope with amino acid synthesis for survival
and growth. We confirmed that cell survival is boosted
after PKC-ζ downregulation in cervix (HeLa) carcinoma
cells in glucose exhaustion conditions (Fig. 4a), but not in
conditions of excess glucose (Fig. 4b), using two independ-
ent clones of HeLa cells constitutively expressing shRNA
against PKC-ζ. We then examined whether the advantage
observed in cell growth upon PKC-ζ downregulation re-
quired the PEPCK-M axis, as it is the only pathway that
connects TCA carbons with routes of amino acid synthe-
sis, as presented above. Treatment with iPEPCK-2 to
block PEPCK-M activity blunted the growth advantage
provided by the downregulation of PKC-ζ (Fig. 4c). This
observation was confirmed in a different model, SW480
colon carcinoma, where downregulation of PKC-ζ pro-
vided a survival advantage in the absence of glucose that
was again lessened when PEPCK-M was inhibited using
iPEPCK-2 (Fig. 4d). Further, we observed strong anti-
correlation fit between PKC-ζ and PEPCK-M (Fig. 4e) in
HeLa sh1-PCK2 cells treated with shRNAs against PKC-ζ,
altogether suggesting cross-regulation of both pathways in
conditions of glucose limitation.
The implication of PEPCK-M in tumor growth in patho-
physiological models
The ability to form spheres in an anchorage-independent
manner (in semisolid media without attachment) is an indi-
cator of tumorigenic and metastatic potential [16, 17], as it
mimics diminished nutrient availability and increased
microenvironment stress in the tumor. HeLa cells grown in
soft agar were able to form spheres after four weeks of in-
cubation (Fig. 5a; shCtrl), and sphere formation was re-
duced severely in PEPCK-M silenced cells (by 70% in sh1-
Fig. 3 PEPCK-M influences proline metabolism. a Concentration of proline in HeLa cells grown for 24 h in high-glucose (25 mM) and glucose
exhaustion (1 mM) conditions. Amount of proline was normalized to mg of protein. Concentration was analyzed by LC-MS. Two-way ANOVA with
Sidak multiple comparison post-test analysis indicate significance versus shCtrl within media treatment (*), significance between sh1-PCK2 and L-
PCK2 within media treatments (#), and significance of media treatment effect ($). b Full 13C enrichment of proline in HeLa cells exposed to 2 mM
[U-13C]glutamine for 4 h in the DMEM media containing 10% dFCS and 0mM glucose. Full incorporation of 13C was analyzed using GC-MS (+4
carbon in GC-MS analysis corresponding to m + 5 on LCMS). One-way ANOVA with Sidak multiple comparison post-test analysis indicate
significance versus shCtrl (*), and significance between sh1-PCK2 and L-PCK2 (#). c 13C enrichment of proline in HeLa cells was exposed to 25 mM
[U-13C]glucose for 4 h in the DMEM media containing 10% dFCS. Incorporation of 13C was determined by the +2 carbon on GC-MS and
corresponded to m + 2 on LCMS. One-way ANOVA with Sidak multiple comparison post-test analysis indicate significance versus shCtrl (*), and
significance between sh1-PCK2 and L-PCK2 (#). d, e Quantitative real-time PCR analysis of PYCR1 (d) and PRODH/POX (e) mRNA expression levels
in HeLa cells grown for 24 h in high-glucose (25 mM) and glucose exhaustion (1 mM) conditions. Values were normalized to shCtrl for each
condition. One-way ANOVA with Sidak multiple comparison post-test analysis indicate significance versus shCtrl (*), and significance between
sh1-PCK2 and L-PCK2 (#). f Proline metabolism pathway and its implications for ROS formation. g, h Production of mitochondrial superoxide in
HeLa cells treated for 3 h in glucose exhaustion (1 mM) (g) and high-glucose (25 mM) (h) conditions. Superoxide was quantified using MitoSOX
fluorescent marker, and mean intensity was measured by flow cytometry. Statistical significance compared with shCtrl was determined by
unpaired two-tailed Student’s t test. i Secretion of proline in high-glucose DMEM media (not containing proline) by HeLa cells after 24 h.
Concentration of proline was normalized to protein and plotted as % of shCtrl secretion. Concentration was analyzed by LC-MS. Statistical
significance between sh1-PCK2 and L-PCK2 was determined by using unpaired two-tailed Student’s t test. j Western blot analysis of p53, p21, and
SOD2 in HeLa cells grown for 24 h in high-glucose (25 mM) and glucose exhaustion (1 mM) conditions. Gamma tubulin was used as loading
control. k Concentration of TCA cycle intermediates in HeLa cells grown 24 h in high-glucose media (25 mM). Concentration of metabolites was
normalized to protein, and fold change was calculated to shCtrl cells. Concentration was analyzed by GC-MS. One-way ANOVA with Sidak
multiple comparison post-test analysis indicate significance versus shCtrl. l Cell viability was measured in HeLa cells using an MTT assay after 48 h
growth in DMEM media lacking glucose with or without supplementation with proline (5 mM). Data are normalized to shCtrl cells grown in the
absence of proline. Statistical significance was determined by using unpaired two-tailed Student’s t test
Hyroššová et al. Cancer & Metabolism             (2021) 9:1 Page 9 of 15
PCK2 and by 43% in sh2-PCK2, when compared to shCtrl)
(Fig. 5a). Similarly, sphere formation was reduced in
PEPCK-M-silenced cells cultured continuously at 1mM
glucose in the media (Fig. 5b). Overexpression of PEPCK-
M in HeLa cells (L-PCK2) slightly increased the number of
spheres; however, this increase was not significant.
Fig. 4 Resistance to glucose deprivation enhanced by PKC-ζ requires PEPCK-M. a, b Effect of PKC-ζ silencing on cell viability. MTT cell viability
assay was measured in HeLa cells growing 72 h in high-glucose media (a) and glucose exhaustion media (b). Fold change was calculated to
values measured at 0 h for each cell line separately. Statistical significance compared with shCtrl was determined by unpaired two-tailed Student’s
t test. c, d MTT cell viability assay of control and PKC-ζ silenced HeLa (c) and SW480 (d) cells treated with inhibitor of PEPCK-M (iPEPCK-2; 5 μM)
or vehicle (DMSO). Cells were grown for 72 h in media lacking glucose. Data was normalized to shPKCζ #Ctrl with DMSO. Statistical significance
compared with shCtrl was determined by unpaired two-tailed Student’s t test. e Spearman’s rank order correlation analysis between the protein
expression levels of PKC-ζ and PEPCK-M in HeLa sh1-PCK2 cells treated with shRNAs against PKC-ζ. Expression levels were quantified in 24
different clones by densitometry of immunoblots
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These results were confirmed in other models using a
pharmacological approach (Fig. 5c, d). Thus, HeLa wild-
type cells or a cell line with constitutive expression of a
mutant Kras in transformed mouse fibroblasts (NIH-
3T3Kras cells) treated with iPEPCK-2 or 3MPA, reduced
sphere formation ~ 83% (Fig. 5c) and ~ 48% (Fig. 5d),
respectively. Interestingly, mass cultures of shRNA-
silenced PEPCK-M cells described here (sh1-PCK2 and
sh2-PCK2) and grown as fat pad grafts in nude mice for
several weeks, reverted to wild-type, shCtrl levels of
Fig. 5 Effects of PEPCK-M activity change on anchorage-independent and xenograft growth. a–d Quantification of anchorage independent
growth of HeLa and NIH-3T3Kras cells. Cells were seeded in semisolid agarose prepared with DMEM media 1:1 and grown for 4 weeks. At the
end of incubation, cells were stained with MTT and number of spheres was counted. HeLa cells were grown in the presence of high-glucose
media (25 mM) (a, c) or glucose exhaustion media (1 mM) (b). During the whole experiment, HeLa shCtrl cells in c were treated with PEPCK-M
inhibitor (iPEPCK-2; 5 μM) or vehicle (DMSO). NIH-3T3Kras cells in d were grown in high-glucose media and treated with PEPCK-M inhibitor
(3MPA; 100 μM) or vehicle (DMSO). Treatment media was refreshed every 3–4 days. Results are presented as fold change to shCtrl or DMSO,
respectively. Statistical significance to shCtrl or DMSO was determined by unpaired two-tailed Student’s t test. e Tumor growth of SW480 WT and
PCK2 CRISPR/Cas9 KO cells implanted into the flanks of BALB/C nude mice. Significance was determined using two-way ANOVA with Sidak
multiple comparison post-test analysis. f Gene expression comparison analysis of tumor samples in the GDC Pan-Can dataset. Tumors presenting
missense (Missense; n = 48) variant mutations are compared to non-variant tumors (FALSE; n = 11542). Unpaired t test analysis with Welch’s
correction was used to determine statistical significance
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PEPCK-M expression suggesting significant selective
pressure in the tumor to favor cells with higher levels of
PEPCK-M (Supplementary Figure 6). Therefore, we de-
signed null mutants (PCK2 CRISPR/Cas9 KO) to further
investigate the capacity of PEPCK-M to sustain tumor
growth in vivo in a xenograft model. A colon carcinoma
model, SW480 was selected instead of HeLa because it
carries only one copy of chromosome 14 where the
PCK2 gene is located, as compared to the multiple cop-
ies found in the HeLa genome, simplifying CRISPR/Cas9
use. These models have been previously characterized
and show similar effects on cellular viability as the HeLa
model of PEPCK-M knockdown presented here [9]. Both
PCK2 CRISPR/Cas9 KO and wild-type (WT) cells were
then injected into the flanks of immunocompromised
NOD/SCID mice and allow to grow in the absence of
external nutritional stress (chow). Tumor growth was
blunted in PCK2 CRISPR/Cas9 KO cells as compared to
WT (Fig. 5e).
Discussion
Metabolic reprogramming is a hallmark of cancer that
helps tumors cope with anabolism and energy demands
for growth and invasion [18]. In this article, we propose
PEPCK-M as a key player in this hallmark when glucose
levels drop and tumors must shift to use other sub-
strates, such as glutamine. An expression signature for
mitochondrial PEPCK (PEPCK-M) is present in most
cancer cells examined. On the contrary, most tumors
analyzed showed very low or no expression of PEPCK-C,
the cytosolic form of this enzyme. Interestingly, the tu-
mors originating from tissues that originally express
cytosolic and mitochondrial isoforms, such as the kidney
and liver, maintain expression of both upon malignancy.
However, PEPCK-C expression levels dropped in these
tumors, as reported elsewhere in hepatocellular carcin-
oma and colon cancer [19, 20]. PEPCK-M expression,
on the other hand, did not decrease as much in the tu-
mors originating from the liver. These data point to a
deleterious impact of gluconeogenic pathways in cancer
progression reinforced by similar behavior for glucose-6
phosphatase and fructose bisphospatase-1 in human ma-
lignancies of gluconeogenic tissues [20, 21]. PEPCK-C
might participate in specific phases of the tumor pro-
gression in adaptative responses that are key to cancer
development as it is suggested by its participation in
some metabolic adaptations in hepatocarcinoma [22]
and melanoma [23].
A clue on the mechanism for the integrative role of
PEPCK-M in cancer metabolism arises from its transcrip-
tion regulation by ATF4 under nutrient stress [24, 25]. In
these conditions, we demonstrate the functional relevance
of the pathway to feed 13C-labeled carbons from glutam-
ine into phosphoenolpyruvate (PEP), serine, and glycine,
demonstrating that cataplerosis of TCA cycle 4-carbon in-
termediates towards PEP, serine, and glycine was specific-
ally dependent on PEPCK-M flux. Even though
enrichment was seemingly low, labeling incubation was
very short by design as we aimed to avoid saturation of
the labeling pattern in various TCA cycle intermediates to
properly assess cataplerosis. It is also important to men-
tion that labeling studies were performed in the presence
of exogenous serine and glycine. This may lead to an
underestimation of isotope labeling due to equilibration
with unlabeled exogenous sources as pointed out by
DeNicola et al. [26]. The nearly linear relationship with
PEPCK-M protein in silenced (sh1-PCK2; ~ 35%), wild-
type (shCtrl; 100%), and overexpressed (L-PCK2; ~250%)
clones suggests a good control of the flux rates towards
this pathway exerted by PEPCK-M, unlike the low control
coefficient shown for PEPCK-C in liver gluconeogenesis
[27]. These data are consistent with the observation from
Vincent et al. that carbons originating from glutamine flux
fed into serine under glucose deprivation via PEPCK-M
[28] in A549 NSCLC cells, known to withstand glucose
deprivation and even proliferate in the presence of glu-
tamine. In contrast, HeLa cells did not cope well with the
severe stress-induced by total glucose depletion as they
stop to grow and total cell number was decreased over
time, although PEPCK-M overexpression did enhance
somewhat the ability of these cells to survive in these
conditions.
PEPCK-M overexpressing cells showed an anabolic
phenotype, with higher serine consumption from the
media (data not shown), and a higher molar fraction of
amino acids synthesized from either PEP (tyrosine), 3PG
(serine and glycine), or intermediaries of the TCA cycle
(aspartate and proline). Besides, proline secretion was
significantly increased in HeLa cells with overexpressed
PEPCK-M which correlated with higher expression of
PYCR enzyme that converts pyrroline-5-carboxylate to
proline, in both glucose concentrations tested. Indeed,
lower proline concentration in PEPCK-M silenced cells,
together with higher expression of POX, an enzyme in-
volved in the catabolism of proline, points to increased
proline turnover or consumption in PEPCK-M limiting
conditions, and supports a role for PEPCK-M in the bio-
synthesis of proline, albeit indirectly.
The importance of proline for cancer growth might also
involve the NADPH/NADP+ equilibrium and the gener-
ation of ROS consequence of proline cycling [29, 30]. Our
data is consistent with this view, and with previous obser-
vations that increased proline metabolism correlated with
higher ROS production at the PRODH/POX node, and a
blockade in TCA cycle flux [15], a general mechanism to
cope with hypoxic stress [31]. These events identify a
metabolic disturbance that bear on the health status of the
cells with reduced PEPCK-M activity (i.e., sh1-PCK2),
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albeit with minimal effects on cell viability and apoptosis
in the absence of nutrient stress [5, 6, 9].
Based on the results shown, and previous data on neur-
onal progenitors suggesting a role for PEPCK-M in ECM
[32], we believe that this pathway might be relevant to the
proteostatic phenotype. In this regard, its role in the con-
trol of the anabolic potential of the cell is very consistent
with the observation that PEPCK-M loss has a greater im-
pact on 3D culture homeostasis (i.e., anchorage-
independent colony formation) than what might be in-
ferred from cell culture silencing studies [6, 7, 9]. More-
over, the synthesis of proline is activated by c-Myc [14],
and PEPCK-M might influence this pathway through its
regulation of calcium fluxes by modulating PEP levels and
SERCA activity in cancer cells [6, 33], that in turn triggers
the CAMKIIγ-dependent phosphorylation and
stabilization of c-Myc. Interestingly, PEPCK-M can impact
on metabolism by regulating the PEP levels even in the
presence of excess glucose in HCT116 cells [6]. However,
in the present study using HeLa cells, we have not been
able to measure specific flux of carbons from glutamine
into serine and glycine in these conditions, even with ex-
tended incubation times. An indirect contribution of
PEPCK-M to the glycolytic flux cannot reconcile these
data since glycolytic flux measured in HCT116 and
SW480 cells with [5-3H]-glucose showed no changes after
PEPCK-M inhibition [6]. A similar conundrum was identi-
fied by Maddocks et al. who detected the formation of un-
labeled serine in HCT116 cells grown in the presence of
fully labeled glucose and the absence of exogenous serine
and glycine [34], pointing to the implication of a different
pathway towards serine synthesis, which might involve
PEPCK-M. This idea is also supported by the
phenomenon occurring in adipocytes, where glyceroneo-
genesis is the main source of triglycerides even in the
presence of glucose [35].
In addition to c-Myc, other central regulators of metabol-
ism in the tumor have recently surfaced that might directly
impact on the PEPCK-M pathway. One such example is
PKC-ζ, a member of the atypical PKC family whose loss
has been shown to enhance glutamine utilization and serine
and glycine synthesis in conditions of glucose deprivation
[10]. The role of PKC-ζ in glucose limiting conditions was
corroborated in our lab both in the HeLa and the SW480
cell models using shRNA. In these models, PEPCK-M was
necessary to support the successful metabolic reprogram-
ming of PKC-ζ loss. Furthermore, regulatory anti-
correlation between PEPCK-M and PKC-ζ levels were ob-
served in several independent clones tested where PKC-ζ
expression was silenced using various sequences of shRNA,
pointing towards the interaction of both pathways in re-
sponse to nutrient stress. The relevance of these findings
for tumor biology is highlighted by an initial analysis of the
expression of PCK2 in tumors from the GDC Pan-Can
dataset showing increased expression of the gene in tumors
presenting missense variant mutations as compared to
non-variant samples (Fig. 5f). This data, together with the
abundant information on the importance of PKC-ζ sup-
pression in tumor growth in vivo [36, 37], support a rele-
vant link between these two pathways in connection with
tumor viability and growth.
Conclusions
All in all, our work described mechanisms for metabolic
flexibility in cancer cells that are dependent on PEPCK-
M activity. PEPCK-M-driven cataplerosis, in sync with
PKC-ζ suppression, adds a dynamic provision of sub-
strates to cancer cells for keeping-up with stress and
promote anabolism.
The mechanism for the supportive role of PEPCK-M
in cancer cells opens a therapeutic window and en-
hances our understanding of cancer metabolism. Finally,
these studies support this enzyme as a target in this
pathology and will serve as a set point for continuing
our development of new therapeutic strategies involving
related pathways.
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Additional file 1: Supplementary Table 1. Oncomine datasets
reference list. Log2 median centered ratio of PCK1 and PCK2 in different
cancers analyzed with Oncomine (https://www.oncomine.org; Rhodes
et al., 2004). Analysis type: Cancer versus Normal, threshold at p=1E-5 and
top gene rank 10%. Missing values for PCK1 expression were not
significant or were not analyzed in given dataset. Reference to original
study is listed.
Additional file 2: Supplementary Figure 1. HeLa model with stable
silencing and overexpression of PEPCK-M. Silencing and overexpression
were obtained using lentiviral vectors containing inserts of shRNA against
PCK2 or inserts of PCK2 cDNA, respectively. (A) Western blot analysis of
mitochondrial and cytosolic PEPCK expression levels in HeLa cells with al-
tered PEPCK-M expression levels: overexpressed (L-PCK2), basal (shCtrl
and WT) and knocked down PEPCK-M (sh1-PCK2 and sh2-PCK2). As a
positive control of PEPCK-C expression, extracts from mouse liver and Fao
hepatoma cells were used. (B) Western blot quantification of PEPCK-M
protein abundance in HeLa modified lines. PEPCK-M expression was nor-
malized by gamma tubulin. Results are represented as fold change to
HeLa WT. One-way Anova with Sidak multiple comparison post-test ana-
lysis indicate significance versus WT. (C) PEPCK-M enzymatic activity in
HeLa shCtrl, sh1-PCK2, sh2-PCK2 and L-PCK2 cells grown in basal condi-
tions was measured by production of NADH. One-way Anova with Sidak
multiple comparison post-test analysis indicate significance versus shCtrl.
Supplementary Figure 2. Time course of glucose depletion under glu-
cose exhaustion conditions. HeLa shCtrl cells were washed 3 times with
PBS and treated with DMEM medium containing 1 mM glucose. Concen-
tration of glucose in medium was measured every 3 h, up to 24 h. Sup-
plementary Figure 3. 13C enrichment of serine and glycine in HeLa
cells. (A) Cells were exposed to 2 mM [U-13C]glutamine for 4 h in the
DMEM media containing 10% dFCS and 25 mM glucose. Incorporation of
13C into proline was analyzed using GC-MS. (B) HeLa shCtrl cells were ex-
posed to 2 mM [U-13C]glutamine for 4 h in the DMEM media containing
10% dFCS and 25 mM glucose or media lacking serine and glycine (MEM)
containing 10% dFCS and 5 mM glucose. Incorporation of 13C was ana-
lyzed using GC-MS. Negative values were set as 0. Supplementary
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Figure 4. PEPCK-M inhibition with iPEPCK-2 effects on viability are
dependent on Ser/Gly. MTT cell viability assay of HeLa shCtrl cells after
72 h of growth in 0 mM glucose MEM media with or without 0.4 mM
serine and 0.4 mM glycine (Ser/Gly). Cells were treated with PEPCK-M in-
hibitor iPEPCK-2 (5 μM). Fold change was calculated to minus Ser/Gly
condition. Significance was determined using two-way Anova with Sidak
multiple comparison post-test analysis. Supplementary Figure 5. Glu-
cose content and PEPCK-M activity modulates Proline metabolism. (A)
Quantitative real time PCR analysis of PYCR1 and PRODH/POX mRNA ex-
pression levels in HeLa cells grown in glucose exhaustion (1 mM) condi-
tions for 24 h. Values were normalized to high glucose (25 mM) condition
which is represented by dotted line. Statistical significance to shCtrl was
determined by using unpaired two-tailed Student's t-test. (B) 13C enrich-
ment of proline in HeLa cells were exposed to 2 mM [U-13C]glutamine for
4 h in the DMEM media containing 10% dFCS and 25 mM glucose. In-
corporation of 13C was analyzed using GC-MS. One-way Anova with Sidak
multiple comparison post-test analysis did not show significant differ-
ences. (C) Proline effects (5 mM) on viability after iPEPCK-2 treatment
(4.3 μM) on HCT116 colon carcinoma cells grown in DMEM media lacking
glucose for 48 h. Cell viability was measured using an MTT assay Statistical
significance was determined by using unpaired two-tailed Student's t-
test. Supplementary Figure 6. Loss of PEPCK-M silencing in xenografts
from HeLa cell clones. (A) Tumor growth of HeLa cells implanted into
mammary fat pad of BALB/C nude mice. One-way Anova with Sidak mul-
tiple comparison post-test analysis did not show significant differences.
(B) Western blot analysis of PEPCK-M in tumors from A. Gamma tubulin
was used as loading control.
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